Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
IPO Year: 2014
Exchange: NASDAQ
Website: immunic-therapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/25/2025 | Outperform | William Blair | |
| 11/25/2024 | $10.00 | Buy | H.C. Wainwright |
| 9/9/2024 | $5.00 | Outperform | Leerink Partners |
| 8/27/2024 | $6.00 | Buy | B. Riley Securities |
| 10/21/2022 | $5.00 | Outperform → Mkt Perform | SVB Leerink |
| 9/19/2022 | $26.00 | Buy | H.C. Wainwright |
| 9/7/2021 | $40.00 → $25.00 | Buy | HC Wainwright & Co. |
4/A - IMMUNIC, INC. (0001280776) (Issuer)
4 - IMMUNIC, INC. (0001280776) (Issuer)
4 - IMMUNIC, INC. (0001280776) (Issuer)
4 - IMMUNIC, INC. (0001280776) (Issuer)
4 - IMMUNIC, INC. (0001280776) (Issuer)
4 - IMMUNIC, INC. (0001280776) (Issuer)
4 - IMMUNIC, INC. (0001280776) (Issuer)
4 - IMMUNIC, INC. (0001280776) (Issuer)
3 - IMMUNIC, INC. (0001280776) (Issuer)
4 - IMMUNIC, INC. (0001280776) (Issuer)
4 - IMMUNIC, INC. (0001280776) (Issuer)
4 - IMMUNIC, INC. (0001280776) (Issuer)
8-K - IMMUNIC, INC. (0001280776) (Filer)
424B5 - IMMUNIC, INC. (0001280776) (Filer)
424B5 - IMMUNIC, INC. (0001280776) (Filer)
8-K - IMMUNIC, INC. (0001280776) (Filer)
10-Q - IMMUNIC, INC. (0001280776) (Filer)
8-K - IMMUNIC, INC. (0001280776) (Filer)
DEFA14A - IMMUNIC, INC. (0001280776) (Filer)
DEF 14A - IMMUNIC, INC. (0001280776) (Filer)
424B5 - IMMUNIC, INC. (0001280776) (Filer)
8-K - IMMUNIC, INC. (0001280776) (Filer)
NEW YORK, June 3, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the closing of its previously announced underwritten public offering of (i) pre-funded warrants to purchase shares of common stock (the "Pre-Funded Warrants"), (ii) series A warrants to purchase shares of common stock (or pre-funded warrants) (the "Series A Warrants"), and (iii) series B warrants to purchase shares of common stock (or pre-funded warrants) (the "Series B Warrants"). The Pre-Funded Warrants are immediately exercisa
NEW YORK, June 2, 2025 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor, scientific and industry conferences in June: June 3-5: Jefferies Healthcare Conference. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will present a company overview on Thursday, June 5, 2025 at 4:55 pm ET at this conference in New York. A webcast will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations.Dr. Vitt, Jason Tardio, President
NEW YORK, May 29, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the pricing of an underwritten public offering of (i) pre-funded warrants to purchase shares of common stock (the "Pre-Funded Warrants"), (ii) series A warrants to purchase shares of common stock (or pre-funded warrants) (the "Series A Warrants"), and (iii) series B warrants to purchase shares of common stock (or pre-funded warrants) (the "Series B Warrants"). The combined public offering price of one Pre-Funded Warrant, one Seri
NEW YORK, May 28, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it has commenced an underwritten public offering of (i) pre-funded warrants to purchase shares of common stock, (ii) Series A warrants to purchase shares of common stock (or pre-funded warrants) expiring on December 31, 2025, (iii) and Series B warrants to purchase shares of common stock (or pre-funded warrants) expiring five years following the issuance date. The Series A and B warrants will immediately expire in proportion
NEW YORK, May 2, 2025 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and industry conferences in May: May 3-6: Digestive Disease Week (DDW). Two abstracts discussing Immunic's phase 1/1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6 (Sirtuin 6), in patients with celiac disease, have been accepted for poster presentations at this conference in San Diego, CA.Poster Title: IMU-856 vs. Placebo Efficacy Effects in Celiac D
– Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even More Prominent 30% Reduction in High Unmet Need Population of Primary Progressive Multiple Sclerosis – – Showed Consistent Reduction of Disability Worsening in Subpopulations Without Inflammatory Lesions at Baseline in Overall Study Population; Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events in Patients Without Gadolinium-Enhancing Lesions at Baseline by 29% Compared to Placebo – – Reduced Annualized Rate of Thalamic Brain Volume Loss by 20% Compared to Placebo – – Confirmed Favorable Safety and Tolerability Observed in Previous Clinical
NEW YORK, April 10, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the closing of its previously announced registered direct offering of 5,666,667 shares of its common stock at a price of $0.90 per share, led by Aberdeen Investments. All securities in the offering were sold by Immunic. The gross proceeds from the offering were approximately $5.1 million before deducting commissions and offering expenses. The offering closed on April 10, 2025. The Company intends to use the net proceeds receive
NEW YORK, April 9, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the pricing of a registered direct offering of 5,666,667 shares of its common stock at the market under Nasdaq rules at a price of $0.90 per share, led by Aberdeen Investments. All securities in the offering are being sold by Immunic. The gross proceeds from the offering are expected to be approximately $5.1 million before deducting commissions and offering expenses. The offering is expected to close on or about April 10, 2025,
NEW YORK, April 1, 2025 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and industry conferences in April: April 5-9: American Academy of Neurology (AAN) 2025 Annual Meeting. Members of Immunic's management, medical and preclinical teams will attend this meeting in San Diego, California. The team will be available throughout the event at booth #2233.April 9-10: German Biotech Days 2025 (Deutsche Biotechnologietage, DBT 2025). Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, wi
NEW YORK, March 3, 2025 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in March: March 4-7: 34th Annual Meeting of the Society for Virology. Two abstracts have been accepted for abstract talk presentations at this conference in Hamburg, Germany. The presentations will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations.Title: Orally Bioavailable RORγ/DHODH Dual Host-Targeting Small Molecu
– 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis Population as well as All Subtypes – – NfL Effect in Non-Active Subpopulation Reinforces Vidofludimus Calcium's Neuroprotective Potential – – Brain Volume Data of the Full 467 CALLIPER Patient Cohort Expected in April 2025 – – Phase 3 ENSURE Program in Relapsing Multiple Sclerosis Ongoing – – Conference Call and Webcast to be Held Tomorrow, October 10, 2023 at 8:00 am ET – NEW YORK, Oct. 9, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chr
– Positive Effects Demonstrated Over Placebo in Four Key Dimensions of Celiac Disease Pathophysiology: Protection of Gut Architecture, Improvement of Patients' Symptoms, Biomarker Response, and Enhancement of Nutrient Absorption – – Corroborates Hypothesized Ability of IMU-856 to Renew Gut Wall and Restore Gut Health – – No Safety or Tolerability Issues Detected – – Conference Call and Webcast to be Held Today, May 4, 2023 at 8:00 am ET – NEW YORK, May 4, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced positive results fro
– 50-Week Maintenance Phase Data Shows Dose-Linear Increase in Clinical Remission for Vidofludimus Calcium as Compared to Placebo – – 30 mg Once-Daily Dose of Vidofludimus Calcium Demonstrated Statistically Significant Rates of Clinical Remission (p=0.0358) and Endoscopic Healing (p=0.0259) at Week 50 – – To Focus Resources on High Performing Vidofludimus Calcium and IMU-856 Programs, Immunic Decided to Deprioritize Izumerogant (IMU-935) Program – – Conference Call and Webcast to be Held today, April 5, 2023 at 8:00 am ET – NEW YORK, April 5, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapi
– Conference Call and Webcast to be Held Today, February 9, 2023, at 11:00 am ET – NEW YORK, Feb. 9, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced that its Celiac Disease R&D Webcast will take place today, February 9, 2023 from 11:00 am to 1:00 pm ET. Management of Immunic, including Daniel Vitt, Ph.D., Chief Executive Officer and President; Andreas Muehler, M.D., M.B.A., Chief Medical Officer; and Hella Kohlhof, Ph.D., Chief Scientific Officer, will be joined by renowned key opinion leaders to discuss the dyna
– Trial Did Not Achieve Primary Endpoint in the Ulcerative Colitis (UC) Population Caused by Unexpected Interference Between Vidofludimus Calcium and Concurrent Use of Corticosteroids – – In UC Population Without Concurrent Steroid Use, Pooled Vidofludimus Calcium Data Suggest Activity in Clinical Remission Over Placebo; Counterbalanced by Interference Observed in the UC Population with Concurrent Steroid Use – – Company Does Not Plan Further Development Activities in Ulcerative Colitis Without a Partner – – Focus to Remain on Ongoing Phase 3 Development of Vidofludimus Calcium in Multiple Sclerosis, and Ongoing IMU-935 and IMU-856 Programs with Clinical Data for Both Expected in 2022 – – $9
SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)
SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)
SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)
SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)
SC 13G - IMMUNIC, INC. (0001280776) (Subject)
SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)
SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)
SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)
SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)
SC 13G - IMMUNIC, INC. (0001280776) (Subject)
William Blair initiated coverage of Immunic with a rating of Outperform
H.C. Wainwright initiated coverage of Immunic with a rating of Buy and set a new price target of $10.00
Leerink Partners resumed coverage of Immunic with a rating of Outperform and set a new price target of $5.00
B. Riley Securities initiated coverage of Immunic with a rating of Buy and set a new price target of $6.00
SVB Leerink downgraded Immunic from Outperform to Mkt Perform and set a new price target of $5.00
H.C. Wainwright resumed coverage of Immunic with a rating of Buy and set a new price target of $26.00
HC Wainwright & Co. reiterated coverage of Immunic with a rating of Buy and set a new price target of $25.00 from $40.00 previously
Aegis Capital initiated coverage of Immunic with a rating of Buy and set a new price target of $55.00
JMP Securities initiated coverage of Immunic with a rating of Market Outperform and set a new price target of $55.00
SVB Leerink resumed coverage of Immunic with a rating of Buy and set a new price target of $45.00
– Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April – – Reported Positive Outcome from Interim Analysis of Ongoing, Twin Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Both Trials on Track to Be Completed in 2026 – – Strengthened Management Team and Board of Directors with Key Hires – – Announced a Three-Tranche Private Placement Totaling Up to $240 Million, Extending Cash Runway Into the Third Quarter of 2025, Based on Initial $80 Million Tranche – NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered,
– Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience – – Served as Neuroimmunology Franchise Head Responsible for Roche's Blockbuster Launch of Multiple Sclerosis Therapy Ocrevus® – NEW YORK, July 24, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the appointment of Simona Skerjanec, M.Pharm, MBA, a thought-leader in brain health with decades of experience in drug development and commercialization, to its board of directors, effective July 22, 2024. Over a nea
– Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic – – Werner Gladdines, Current Vice President, Program Management & Clinical Development Operations, Promoted to Chief Development Officer – NEW YORK, July 9, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that seasoned biopharmaceutical executive, Jason Tardio, will be joining the company as Chief Operating Officer and President, effective July 12, 2024. In the newly created role, Mr. Tardio will lead in
– Thought-Leader in Multiple Sclerosis with Decades of Experience in Academic Medicine and the Pharmaceutical Industry – NEW YORK, April 27, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the appointment of Richard Rudick, M.D., a thought-leader in multiple sclerosis with decades of experience in the clinic, academia and industry, to its board of directors, effective April 26, 2023. The company also announced that Vincent Ossipow, Ph.D., will step down from the Board, effective June 28, 2023. "We are very grateful to have
– Global Commercial Executive Brings 20 Years of Sales and Marketing Expertise –– Jan Van den Bossche Steps Down from Board After Six Year Tenure – NEW YORK , July 6, 2022 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced the appointment of Maria Törnsén, an industry executive with 20 years of global commercial experience in U.S. and ex-U.S. markets, to its Board of Directors, effective July 5, 2022. The company also announced that Jan Van den Bossche has stepped down from the Board, effective July 5, 2022. "Maria
NEW YORK, Oct. 14, 2021 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the appointment of Patrick Walsh as Chief Business Officer, effective today. In this newly created role, Mr. Walsh will be responsible for business development, including strategic partnering opportunities, and will become part of the executive management team of Immunic. "Patrick is a seasoned business development executive who has spent his career helping to successfully build a number of public biopharmaceutical companies. He brings to Immunic
NEW YORK, June 1, 2021 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, announced the appointment of Inderpal Singh as General Counsel, effective today. In his new role, Mr. Singh will be responsible for legal and compliance matters and will become part of the management team of Immunic. "Inderpal is a seasoned legal executive, having spent 20 years in-house, advising several of the world's largest life sciences companies. As such, he brings to Immunic extensive legal knowledge related to clinical development, operations, regulato